GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » GF Value

icad (ICAD) GF Value : $2.13 (As of Apr. 30, 2024)


View and export this data going back to 1992. Start your Free Trial

What is icad GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-30), icad's share price is $1.48. icad's GF Value is $2.13. Therefore, icad's Price-to-GF-Value for today is 0.69.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes icad is Possible Value Trap, Think Twice.


icad  (NAS:ICAD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

icad's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=1.48/2.13
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


icad GF Value Related Terms

Thank you for viewing the detailed overview of icad's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


icad (ICAD) Business Description

Traded in Other Exchanges
N/A
Address
98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Executives
Eric Lonnqvist officer: See Remarks 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea officer: See Remarks 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go officer: Sr. VP of R&D C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno officer: See Remarks C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine director 82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton director C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood director 845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein director C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter officer: See Remarks C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens officer: Executive VP of Marketing C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado officer: Interim Chief FinancialOfficer 98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel director 15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard director C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831